Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?

Acta Neuropathologica

Volumn 127, Issue 6, 2014, Pages 803-810

  Watt, Andrew D ^a,b   Crespi, Gabriela A N ^c   Down, Russell A ^a,b   Ascher, David B ^c   Gunn, Adam ^a,b   Perez, Keyla A ^a,b   McLean, Catriona A ^a,d   Villemagne, Victor L ^a,e   Parker, Michael W ^a,c   Barnham, Kevin J ^a,b   Miles, Luke A ^a,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT'S INSTITUTE OF MEDICAL RESEARCH   (Australia)

^d ALFRED HOSPITAL   (Australia)

^e AUSTIN HEALTH   (Australia)

Author keywords

Alzheimer's disease; Bapineuzumab; Crenezumab; Mass spectrometry; Solanezumab; Amyloid

Indexed keywords

AMYLOID BETA PROTEIN; BAPINEUZUMAB; CRENEZUMAB; EPITOPE; SOLANEZUMAB;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL TISSUE; ARTICLE; CROSS REACTION; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECEPTOR AFFINITY; SURFACE PLASMON RESONANCE; TRANSGENIC MOUSE;

EID: 84901635792     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-014-1290-2     Document Type: Article

References (35)

1. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356. doi:10.1126/science.1072994 (Pubitemid 34790756)
2. Masters CL, Cappai R, Barnham KJ, Villemagne VL (2006) Molecular mechanisms for alzheimer's disease: implications for neuroimaging and therapeutics. J Neurochem 97:1700-1725 (Pubitemid 43873662)
3. Miles LA, Crespi GAN, Doughty L, Parker MW (2013) Bapineuzumab captures the n-terminus of the alzheimer's disease amy-loid- beta peptide in a helical conformation. Sci Rep 3. http://www.nature.com/srep/2013/130218/srep01302/abs/ srep01302.html#supplementary-information
4. Blennow K, Zetterberg H, Rinne JO et al (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate alzheimer disease. Arch Neurol 69:1002-1010. doi:10.1001/archneurol. 2012.90
5. Rinne JO, Brooks DJ, Rossor MN et al (2010) 11c-pib pet assessment of change in fibrillar amyloid-β load in patients with alzheimer's disease treated with bapineuzumab: a phase 2, doubleblind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363-372. doi:10.1016/S1474-4422(10)70043-0
6. Sperling R, Salloway S, Brooks DJ et al (2012) Amyloid-related imaging abnormalities in patients with alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11:241-249. doi:10.1016/s1474-4422(12) 70015-7
7. Imbimbo BP, Ottonello S, Frisardi V et al (2012) Solanezumab for the treatment of mild-to-moderate alzheimer's disease. Expert Rev Clin Immunol 8:135-149. doi:10.1586/eci.11.93
8. Seubert P, Barbour R, Khan K et al (2008) Antibody capture of soluble abeta does not reduce cortical abeta amyloidosis in the pdapp mouse. Neurodegener Dis 5:65-71. doi:10.1159/000112834
9. Citron M (2010) Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9:387-398. doi:10.1038/nrd2896
10. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-a beta antibody alters cns and plasma a beta clearance and decreases brain a beta burden in a mouse model of alzheimer's disease. Proc Natl Acad Sci USA 98:8850-8855. doi:10.1073/pnas.151261398 (Pubitemid 32678116)
11. Mullard A (2012) Sting of alzheimer's failures offset by upcoming prevention trials. Nat Rev Drug Discov 11:657-660. doi:10.1038/nrd3842
12. Adolfsson O, Pihlgren M, Toni N et al (2012) An effector-reduced anti-β-amyloid (aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of aβ. J Neurosci 32:9677-9689. doi:10.1523/jneurosci.4742-11.2012
13. Reiman EM, Langbaum JB, Fleisher AS et al (2011) Alzheimer's prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26(Suppl 3):321-329. doi:10.3233/jad-2011-0059
14. World Health Organisation (2008) Proposed inn: List 100. WHO Drug Inform 22
15. World Health Organisation (2011) Poposed inn: List 105. WHO Drug Inform 25
16. Schroeter S, Games KD (2008) Prevention and treatment of cerebral amyloid angiopathy: Us 12/106,206. US Patent Application
17. Bales KR, Demattos R, Holtzman DM, Paul SM, Tsurushita N, Vasquez M (2001) Humanized antibodies that sequester amyloid beta peptide. US Patent Application
18. Pfeifer A, Pihlgren M, Muhs AW, Ryan, Nicolau C, Greferath R (2008) Humanized antibodies to amyloid beta. US Patent Application
19. Kok WM, Scanlon DB, Karas JA et al (2009) Solid-phase synthesis of homodimeric peptides: Preparation of covalentlylinked dimers of amyloid [small beta] peptide. Chem Commun. doi:10.1039/B912784D (6228-6230)
20. Watt AD, Perez KA, Rembach A et al (2013) Oligomers, fact or artefact? Sds-page induces dimerization of beta-amyloid in human brain samples. Acta Neuropathol 125:549-564. doi:10.1007/s00401-013-1083-z
21. Ellis KA, Bush AI, Darby D et al (2009) The australian imaging, biomarkers and lifestyle (aibl) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of alzheimer's disease. Int Psychogeriatr 21:672-687. doi:10.1017/S1041610209009405
22. Villemagne VL, Perez KA, Pike KE et al (2010) Blood borne amyloid-beta dimer correlates with clinical markers of alzheimer's disease. J Neurosci 30:6315-6322
23. Koenig T, Menze BH, Kirchner M et al (2008) Robust prediction of the mascot score for an improved quality assessment in mass spectrometric proteomics. J Proteome Res 7:3708-3717. doi:10.1021/pr700859x
24. Perkins DN, Pappin DJC, Creasy DM, Cottrell JS (1999) Probabil-ity- based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20:3551-3567. doi:10.1002/(SICI)1522-2683(19991201)20: 18〈3551:AID- ELPS3551〉3.0.CO;2-2
25. Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF (2005) Pharmacokinetic analysis of the bloodbrain barrier transport of 125i-amyloid β protein 40 in wild-type and alzheimer's disease transgenic mice (app, ps1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther 313:1370-1378. doi:10.1124/jpet.104.081901 (Pubitemid 40727044)
26. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368:387-403 (Pubitemid 44108123)
27. Villemagne VL, Burnham S, Bourgeat P et al (2013) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic alzheimer's disease: a prospective cohort study. Lancet Neurol 12:357-367. doi:10.1016/S1474-4422(13)70044-9
28. Selkoe DJ (2011) Resolving controversies on the path to alzheimer's therapeutics. Nat Med 17:1060-1065
29. Sperling RA, Jack CR, Aisen PS (2011) Testing the right target and right drug at the right stage. Sci Transl Med 3:111-133. doi:10.1126/scitranslmed. 3002609
30. Watt AD, Villemagne VL, Barnham KJ (2013) Metals, membranes, and amyloid-beta oligomers: key pieces in the alzheimer's disease puzzle? J Alzheimers Dis 33(Suppl 1):283-293. doi:10.3233/jad-2012-129017
31. Pontecorvo M, Joshi A, Lu Met al. (2013) Relationship between solanezumab treatment and amyloid burden in mild to moderate ad patients. In: 7th Human Amyloid Imaging (HAI)
32. Vom Berg J, Prokop S, Miller KR et al (2012) Inhibition of il-12/il-23 signaling reduces alzheimer's disease-like pathology and cognitive decline. Nat Med 18:1812-1819. doi:10.1038/nm.2965
33. Berglund L, Andrade J, Odeberg J, Uhlén M (2008) The epitope space of the human proteome. Protein Sci 17:606-613. doi:10.1110/ps.073347208 (Pubitemid 351480854)
34. Bonnycastle L, Mehroke JS, Rashed M, Gong X, Scott JK (1996) Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. J Mol Biol 258:747-762. doi:10.1006/jmbi.1996. 0284 (Pubitemid 26150878)
35. James LC, Roversi P, Tawfik DS (2003) Antibody multispecificity mediated by conformational diversity. Science 299:1362-1367. doi:10.1126/science.1079731 (Pubitemid 36254643)